Deutsche Bank Starts Alexion Pharmaceuticals (ALXN) at Buy
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Deutsche Bank initiates coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Buy rating and a price target of $164.
Analyst Andrew Peters said, "While ALXN has underperformed in 2016 along with the rest of biotech, we believe this weakness is not simply a sector-wide effect, but instead likely reflects concerns over multiple expansion in the face of slowing growth and emerging competition in the complement inhibitor landscape. Looking at these risks however we see reasons to be bullish on Alexion and point to 3Q16 results as illustrative of the potential path forward for continued growth and a pipeline-based strategy to counter potential competitive and biosimilar pressure."
Shares of Alexion Pharmaceuticals closed at $127.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Cuts Price Target on Neurocrine Biosciences (NBIX) Following Study
- Neurocrine Bio. (NBIX) PT Lowered to $56 at Jefferies Amid Adult Tourette's Data
- Stifel Starts Enable Midstream Partners (ENBL) at Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!